Our Team

CEO and President

Eddine Saiah is seasoned and scientifically trained executive with leadership experience in venture, biotech, and global pharmaceutical companies. Dr. Saiah has been with Stablix since May 2022 when he joined the company as Chief Scientific Officer before his promotion to CEO in 2025. Previously, Dr. Saiah was CSO at Navitor Pharmaceuticals and help advance the company from concept to clinical stage. Dr. Saiah also worked at Atlas Venture as an entrepreneur in residence where he contributed to company creation from concept to series A funding. Dr Saiah held a series of leadership positions with increasing responsibilities at Wyeth and Pfizer working on a wide range of therapeutic areas including inflammation, immunology, cardiometabolic and rare disease. Dr. Saiah in the author and coinventor of over 120 publications and patents. He holds a Ph.D. in chemistry from Paris Sorbonne University/Pierre and Marie Curie and completed postdoctoral training at the Mayo Clinic.